Last reviewed · How we verify
CT-P17 SC
CT-P17 SC is a subcutaneous formulation of a monoclonal antibody targeting TNF-alpha to reduce inflammatory cytokine signaling.
CT-P17 SC is a subcutaneous formulation of a monoclonal antibody targeting TNF-alpha to reduce inflammatory cytokine signaling. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.
At a glance
| Generic name | CT-P17 SC |
|---|---|
| Sponsor | Celltrion |
| Drug class | TNF-alpha inhibitor monoclonal antibody (biosimilar) |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
CT-P17 is a biosimilar of adalimumab (Humira), a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha, a key pro-inflammatory cytokine. By neutralizing TNF-alpha, the drug suppresses inflammatory immune responses in autoimmune and inflammatory conditions. The SC (subcutaneous) formulation allows for patient self-administration.
Approved indications
- Rheumatoid arthritis
- Ankylosing spondylitis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Increased infection risk
- Tuberculosis reactivation
Key clinical trials
- To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects (PHASE1)
- A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis (PHASE3)
- A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |